# Sentien Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sentien-biotechnologies

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.sentienbiotech.com
- Total disclosed funding: $12M
- Latest round: Series A (Apr 4, 2017)
- Investors on record: 6

## About

Sentien Biotechnologies, Inc. focuses on developing innovative biotherapeutic solutions targeting various medical conditions through its proprietary technology in regenerative medicine.Founded in 2008 and headquartered in Cambridge, US, Sentien Biotechnologies, Inc. is dedicated to creating advanced therapies that leverage its unique platform. The company has undergone changes in its strategic direction over the years but remains focused on therapeutic innovations in the biotech sector. The firm was co-founded by Biju Parekkadan and Brian Miller, who has a history of involvement in the biotechnology field. Sentien received a total investment of USD 12.00 mn in its Series A funding round on April 4, 2017, co-led by BioInnovation Capital and Boehringer Ingelheim Venture, with participation from investors including Chiesi Ventures, Mass Medical Angels, and MBL Venture Capital.Sentien Biotechnologies, Inc. specializes in innovative biotherapeutic solutions, providing advanced products designed to enhance treatment efficiency across healthcare. Their offerings cater to various medical needs, focusing on regenerative medicine. The company primarily targets healthcare providers in North America, Europe, and select regions in Asia looking for effective solutions to address patient care challenges.Sentien Biotechnologies, Inc. generates revenue through direct sales and strategic partnerships, primarily engaging in B2B agreements. Clients typically purchase product licenses or subscribe to services that include ongoing support and updates. The revenue model supports a tiered pricing plan, ensuring products are accessible to both large healthcare organizations and smaller providers, thereby reinforcing the company's market presence.Looking ahead, Sentien Biotechnologies, Inc. plans to introduce several new products aimed at enhancing patient outcomes in regenerative medicine. The company seeks to expand its market reach, specifically targeting new regions across Asia and Europe by the end of 2024. The recent Series A funding of USD 12.00 mn will be utilized to further develop these new therapies and support market expansion strategies, enhancing the ability to address diverse medical challenges.

## Funding rounds

- Series A, Apr 4, 2017, $12M — Life Science Venture Capital, Boehringer Ingelheim Venture, Mass Medical Angels, Chiesi Ventures, Mission Biocapital
- Series A, Aug 10, 2015 — Boehringer Ingelheim Venture, Portage  Biotech Inc.

## Investors

- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A
- Portage  Biotech Inc. — Series A
- Life Science Venture Capital (https://capitalatlas.ai/funds/life-science-venture-capital) — Series A
- Mass Medical Angels — Series A
- Chiesi Ventures (https://capitalatlas.ai/funds/chiesi-ventures) — Series A
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series A